NYSE American - Delayed Quote USD

Oragenics, Inc. (OGEN)

1.6700 -0.0500 (-2.91%)
At close: June 7 at 3:39 PM EDT
1.6800 +0.01 (+0.60%)
After hours: June 7 at 7:35 PM EDT
Loading Chart for OGEN
DELL
  • Previous Close 1.7200
  • Open 1.7000
  • Bid 1.6500 x 800
  • Ask 1.7600 x 1200
  • Day's Range 1.6617 - 1.7699
  • 52 Week Range 1.0000 - 7.7400
  • Volume 33,163
  • Avg. Volume 111,258
  • Market Cap (intraday) 7.483M
  • Beta (5Y Monthly) 0.57
  • PE Ratio (TTM) --
  • EPS (TTM) -8.4700
  • Earnings Date Aug 9, 2024 - Aug 13, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The company also develops NT-CoV2-1, a SARS-CoV-2 vaccine product candidate; and Lantibiotic Product Candidate, such as Mutacin 1140 (MU1140), a molecule belonging to the novel class of antibiotics. It has a license agreement with Inspirevax Inc. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.

www.oragenics.com

5

Full Time Employees

December 31

Fiscal Year Ends

Recent News: OGEN

Performance Overview: OGEN

Trailing total returns as of 6/7/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

OGEN
70.34%
S&P 500
12.10%

1-Year Return

OGEN
44.33%
S&P 500
24.82%

3-Year Return

OGEN
96.13%
S&P 500
26.41%

5-Year Return

OGEN
94.20%
S&P 500
88.04%

Compare To: OGEN

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: OGEN

Valuation Measures

Annual
As of 1/5/2024
  • Market Cap

    7.48M

  • Enterprise Value

    7.13M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    7.25

  • Enterprise Value/Revenue

    105.83

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -163.28%

  • Return on Equity (ttm)

    -314.88%

  • Revenue (ttm)

    20.63k

  • Net Income Avi to Common (ttm)

    -20.26M

  • Diluted EPS (ttm)

    -8.4700

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.07M

  • Total Debt/Equity (mrq)

    4.83%

  • Levered Free Cash Flow (ttm)

    -10.3M

Research Analysis: OGEN

Company Insights: OGEN

Research Reports: OGEN

People Also Watch